# RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies

> **NCT04844086** · PHASE1 · TERMINATED · sponsor: **Eden BioCell Ltd.** · enrollment: 2 (actual)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia
- Non-Hodgkin's Lymphoma, Relapsed
- Non-Hodgkin's Lymphoma Refractory
- Primary Mediastinal Large B Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- High-grade B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** RPM CD19-mbIL15-CAR-T cells

## Key facts

- **NCT ID:** NCT04844086
- **Lead sponsor:** Eden BioCell Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-02
- **Primary completion:** 2022-05-12
- **Final completion:** 2022-05-12
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** CAR-T manufacturing technology can not meet the dose requirement for clinical patients.
- **Last updated:** 2022-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04844086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04844086, "RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04844086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*